Generic Name and Formulations:
Miglitol 25mg, 50mg, 100mg; tabs.
Indications for GLYSET:
Adjunct to diet in type 2 diabetes, alone or with a sulfonylurea.
Take with the first bite of each main meal. Initially 25mg three times daily; may start at 25mg once daily (to minimize GI effects) and gradually increase to 25mg three times daily. Increase to 50mg three times daily after 4–8 weeks; usual max 100mg three times daily.
Ketoacidosis. Inflammatory bowel disease. Colonic ulceration. Partial intestinal obstruction or predisposition thereof. Chronic intestinal diseases associated with marked disorders of digestion or absorption. Conditions that may deteriorate from increased intestinal gas formation.
Significant renal dysfunction (serum creatinine >2mg/dL): not recommended. Use glucose, not sucrose, to treat hypoglycemia. Stress. Monitor 1-hour postprandial blood glucose initially and during titration then glycosylated hemoglobin. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended.
Antagonized by intestinal adsorbents (eg, charcoal), pancreatin, amylase, other carbohydrate-splitting enzymes. May decrease levels of ranitidine, propranolol. Risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing dose of these.
Transient flatulence, diarrhea, abdominal pain; low serum iron.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy